VOL 72 No 1 January 2023
DOI: 10.12788/jfp.0515

Basal Insulin/GLP-1 RA Fixed-Ratio Combinations as an Option for Advancement of Basal Insulin Therapy in Older Adults With Type 2 Diabetes

The prevalence of type 2 diabetes (T2D) is increasing, and owing to the aging population, the number of older adults with T2D is growing rapidly. By virtue of their age, older adults are likely to have been living with the disease longer than their younger counterparts. This, coupled with differences in T2D pathophysiology between younger and older patients, means that older adults often require advancement of treatment from basal insulin. However, older adults with T2D represent a heterogeneous population, for whom the goals of treatment are complex, and overtreatment can increase the risk of complications. These factors highlight the need for individualized glycemic targets and therapeutic strategies. In this roundtable, the authors discuss the management of older adults with T2D--a large patient population who often require treatment simplification.

Video 1: Introduction

Video 1: Introduction

Video 2: Unique Pathophysiology of Type 2 Diabetes in Older Adults

Video 3: Treatment Considerations When Managing Older Adults With Type 2 Diabetes

Video 4: Advancement of Basal Insulin Therapy: Options for Older Adults

Video 5: Simplification and/or Deintensification of Complex Insulin Regimens

Video 6: Practical Tips for Choosing Appropriate Therapy for Older Adults With Type 2 Diabetes


About the Panel

Mark Corriere, MD, FACP  Photo

Mark Corriere, MD, FACP

is an endocrinologist at Maryland Endocrine and Diabetes in Columbia, Maryland.

Brian Burtch, MD Photo

Brian Burtch, MD

is an endocrinolgist and the director of diabetes education at University Hospitals Lake Health Physician Group in Mentor, Ohio.

Naushira Pandya, MD, CMD, FACP Photo

Naushira Pandya, MD, CMD, FACP

is a professor and chair of the Department of Geriatrics at Nova Southeastern University (NSU), Kiran C. Patel College of Osteopathic Medicine, and project director of the Health Resources & Services Administration-funded NSU South Florida Geriatrics Workforce Enhancement Program.


This peer-reviewed publication was developed in adherence with Good Publication Practice (GPP3) guidelines. All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship and have disclosed all potential conflicts of interest.

Mark Corriere, MD, FACP
Speakers’ bureau for AbbVie, AstraZeneca, Bayer, Eli Lilly and Company, Novo Nordisk, Sanofi, Zealand

Brian Burtch, MD
Speakers’ bureau for Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Sanofi

Naushira Pandya, MD, CMD, FACP
Speaker for Eli Lilly and Company


This digital publication was funded by Sanofi US. The authors received writing and editorial support in the preparation of the material provided by Helen Jones, PhD, of Evidence Scientific Solutions, funded by Sanofi US.